论文部分内容阅读
目的观察高血压脑出血患者于疾病早期选择扩血管药物完成治疗后获得的临床效果。方法 73例高血压脑出血患者,随机分为B1组(37例)和B2组(36例)。B1组于发病后的5~7 d开始对患者选择扩血管药物进行治疗;B2组于发病的1个月内未选择扩血管药物进行治疗。对比两组患者在临床疗效以及平均疗程两方面存在的差异。结果在临床治疗效果方面,B1组总有效率明显高于B2组(P<0.05);在平均疗程方面,B1组脑出血患者明显短于B2组(P<0.05)。结论针对高血压脑出血患者,于疾病早期选择扩血管药物进行治疗,能够有效控制患者的疾病情况,可有效控制患者的意识状态,改善患者的脑部缺血情况,最终获得显著的临床治疗效果。
Objective To observe the clinical effects of hypertensive intracerebral hemorrhage (ICH) patients treated with vasodilator selected early in the disease. Methods 73 patients with hypertensive cerebral hemorrhage were randomly divided into B1 group (37 cases) and B2 group (36 cases). In group B1, vasodilator drugs were selected for treatment in patients 5-7 days after onset. In group B2, no vasodilator drugs were selected for treatment within 1 month of onset. The difference between the two groups in clinical efficacy and the average course of treatment was compared. Results In clinical treatment, the total effective rate in group B1 was significantly higher than that in group B2 (P <0.05). The mean duration of treatment was significantly shorter in group B1 than in group B2 (P <0.05). Conclusion For the patients with hypertensive intracerebral hemorrhage, vasodilator drugs can be selected early in the disease, which can effectively control the patient’s disease status, effectively control the patient’s state of consciousness and improve the ischemic situation of the patients, finally obtaining a significant clinical treatment effect .